Cargando…
αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib
Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies in China. In particular, advanced/refractory ovarian cancer lacks effective targeted therapies due to the immunosuppressive and proangiogenic tumor microenvironment. Mesothelin (MSLN) has been found to be...
Autores principales: | Fang, Juemin, Ding, Na, Guo, Xianling, Sun, Yan, Zhang, Zhiwei, Xie, Bailu, Li, Zhong, Wang, Hui, Mao, Wei, Lin, Zhicai, Qin, Fei, Yuan, Min, Chu, Wenqi, Qin, Huanlong, Qian, Qijun, Xu, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887368/ https://www.ncbi.nlm.nih.gov/pubmed/33589520 http://dx.doi.org/10.1136/jitc-2020-001162 |
Ejemplares similares
-
PGE2-EP2/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer
por: Akbari, Behnia, et al.
Publicado: (2023) -
The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer
por: Akbari, Behnia, et al.
Publicado: (2023) -
Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022) -
Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022) -
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)